Supervivientes a largo plazo con Inmunoterapia. Melanoma Avanzado. Prueba de concepto. Combinación de Inmunoterapias
|
Supervivientes a largo plazo con Inmunoterapia.Melanoma Avanzado. Prueba de concepto. Combinación de Inmunoterapias |
1 |
|
Long Survival in Melanoma |
2 |
|
Improved Survival: Anti-CTL-4 |
3 |
|
Pooled OS Analysis Including EAP Data: 4846 Patients |
4 |
|
Phase III: Pembrolizumab vs Ipilimumab |
5 |
|
Phase III CA 209-066: Nivolumab |
6 |
|
CA209-003: Overall Survival at 5-years |
7 |
|
Chekmate 067: Study Design |
8 |
|
CA 209-067: Overall Survival |
9 |
|
Número de diapositiva 10 |
10 |
|
End- Points in advanced melanoma ? |
11 |
|
Outcome of CR patients after treatment cessation:Overwiew |
12 |
|
Número de diapositiva 13 |
13 |
|
Número de diapositiva 14 |
14 |
|
Patients Alive and Off study at 3y Analysis |
15 |
|
Patients Alive at 3 y- On and Off Treatment |
16 |
|
Safety Summary |
17 |
|
CA 209-511: Phase IIIb/IV, Randomized, Double Blinded |
18 |
|
Número de diapositiva 19 |
19 |
|
Número de diapositiva 20 |
20 |
|
Número de diapositiva 21 |
21 |
|
Expected benefit from enhanced patient selection |
22 |
|
New Biomarkers for Immunotherapy |
23 |
|
Treatment based on patient’s characteristics |
24 |
|
Conclusions |
25 |